Ajanta Pharma Ltd Stock Price Today (NSE: AJANTPHARM)
Fundamental Score
Ajanta Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ajanta Pharma Ltd share price today is ₹3079.40, down 0.01% on NSE/BSE as of 17 June 2026. Ajanta Pharma Ltd (AJANTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹32.08K (Cr). The 52-week high for AJANTPHARM share price is ₹3314.90 and the 52-week low is ₹2329.90. At a P/E ratio of 32.94x, AJANTPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 24.91% and a debt-to-equity ratio of 0.06.
Ajanta Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Ajanta Pharma Ltd share price chart: 7.65% return over the past month. 52-week high ₹3314.90, 52-week low ₹2329.90.
Ajanta Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2900.00 | ₹2942.00 | ₹2865.00 | ₹2912.20 | 78.36K (Cr) | |
| ₹2936.30 | ₹3028.90 | ₹2870.70 | ₹2931.00 | 2.23L (Cr) | |
| ₹3038.90 | ₹3060.40 | ₹2850.00 | ₹2928.90 | 2.27L (Cr) | |
| ₹3100.10 | ₹3120.00 | ₹3010.00 | ₹3020.80 | 1.54L (Cr) | |
| ₹3081.50 | ₹3123.90 | ₹3075.70 | ₹3097.10 | 84.04K (Cr) | |
| ₹3119.80 | ₹3137.30 | ₹3070.00 | ₹3081.50 | 48.67K (Cr) | |
| ₹3151.00 | ₹3164.60 | ₹3098.50 | ₹3107.50 | 40.21K (Cr) | |
| ₹3213.50 | ₹3220.00 | ₹3140.10 | ₹3149.20 | 54.08K (Cr) | |
| ₹3250.00 | ₹3258.00 | ₹3182.00 | ₹3188.80 | 47.93K (Cr) | |
| ₹3249.10 | ₹3314.90 | ₹3172.10 | ₹3248.20 | 1.58L (Cr) |
Ajanta Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2936.30 | ₹3028.90 | ₹2865.00 | ₹2912.20 | -0.82% | |
| ₹2868.40 | ₹3314.90 | ₹2850.00 | ₹2928.90 | +2.11% | |
| ₹2849.90 | ₹2934.00 | ₹2696.60 | ₹2822.70 | -0.95% | |
| ₹2830.00 | ₹3228.00 | ₹2739.10 | ₹2805.10 | -0.88% | |
| ₹2810.00 | ₹3054.00 | ₹2756.90 | ₹2993.90 | +6.54% | |
| ₹2787.60 | ₹3020.80 | ₹2654.50 | ₹2781.90 | -0.20% | |
| ₹2565.00 | ₹2824.00 | ₹2513.60 | ₹2768.90 | +7.95% | |
| ₹2483.60 | ₹2622.00 | ₹2445.80 | ₹2560.80 | +3.11% | |
| ₹2391.00 | ₹2511.00 | ₹2379.30 | ₹2465.30 | +3.11% | |
| ₹2505.00 | ₹2627.50 | ₹2329.90 | ₹2406.30 | -3.94% | |
| ₹2779.90 | ₹2792.90 | ₹2449.60 | ₹2477.60 | -10.87% | |
| ₹2590.00 | ₹2875.20 | ₹2494.00 | ₹2751.40 | +6.23% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Overvalued branded generics play; regulatory risks and stretched valuation limit upside.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Ajanta Pharma closed its trading window on April 1, 2026, in anticipation of Q4 and full fiscal year results. Recent news highlights India Pharma 2026, which emphasized funding, infrastructure, and innovation in the Indian pharmaceutical sector.
CORE STORY (THE REAL GAME)
- Q3FY26 earnings beat expectations
- In-licensing agreement with Biocon
- Strong presence in emerging markets
- Faster ANDA approvals in the US
- Successful acquisitions to fill therapy gaps
- New product launches in emerging markets
- High P/E ratio compared to industry average
- Promoter pledging at 15.28%
- Past SEBI scrutiny for insider trading
FII decreased holdings by 0.33%, while DII increased holdings by 0.4%. Promoter holdings decreased slightly by 0.02%.
Indian pharma sector is transitioning towards API backward integration, but Ajanta's focus remains on formulations.
No major news found after live search.
Yes - Free Cash Flow 5Y: ₹2953.5 Cr.
Expect 17% EBITDA/PAT CAGR over FY26-28E. Focus on branded generics and ANDA approvals will drive growth.
Primary Thesis Risk
Regulatory hurdles in key markets can derail growth.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ajanta Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ajanta Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AJANTPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (24.91%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.37%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.53%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (20.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (12.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (15.34% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (56.18x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2953.50 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (66.24%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.43%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Ajanta Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ajanta Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ajanta Pharma LtdAjanta Pharma L...Selected✓ AJANTPHARM • 532331 | 53.5/100 | ₹3079.40₹3079 | ₹32076.12₹32076.12 | 32.94Average 32.9 Average | 24.91%Excellent 24.91% Excellent | 32.37%Excellent 32.37% Excellent | 0.06Excellent 0.1 Excellent | 14.26%Good 14.26% Good | 12.43%Good 12.43% Good | 1.09% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Ajanta Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for AJANTPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹73.53 | ₹2768.90 | 37.7x |
| FY 2024 | ₹64.77 | ₹2932.20 | 45.3x |
| FY 2023 | ₹45.89 | ₹2083.65 | 45.4x |
| FY 2022 | ₹54.96 | ₹1211.95 | 22.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ajanta Pharma Ltd Dividend History
Annual cash dividends paid by AJANTPHARM — dividend yield 1.09%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹349.37 Cr |
| FY 2024 | ₹642.17 Cr |
| FY 2023 | ₹89.69 Cr |
| FY 2022 | ₹82.21 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Ajanta Pharma Ltd Quarterly Performance
Latest quarterly metrics for AJANTPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
14.08%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
20.19%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.43%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
14.26%
Compounded annual net profit growth over 5 years
Ajanta Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AJANTPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ajanta Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ajanta Pharma Ltd (AJANTPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ajanta Pharma Ltd
About AJANTPHARM (Ajanta Pharma Ltd)
Ajanta Pharma Ltd is a dynamic pharmaceutical company committed to developing and delivering innovative healthcare solutions across a diverse range of therapeutic areas. With a foc...us on specialty pharmaceutical formulations, Ajanta Pharma blends scientific expertise with cutting-edge manufacturing processes to create high-quality medicines designed to address unmet medical needs. The company's product portfolio encompasses a broad spectrum of dosage forms, from conventional tablets and capsules to advanced injectables and inhalers, reflecting its dedication to providing versatile treatment options for patients. Ajanta Pharma's unwavering pursuit of excellence drives its commitment to research and development, enabling it to consistently introduce novel products that improve patient outcomes and enhance the quality of life. Ajanta Pharma's strategic approach to the pharmaceutical market involves a dual focus on chronic and acute therapies, catering to both long-term health management and immediate medical interventions. This comprehensive strategy allows the company to address a wide range of patient needs and contribute to overall healthcare advancement. The company's branded generic products are recognized for their reliability and affordability, making essential medications accessible to a broader population. Ajanta Pharma's dedication to quality extends beyond its product offerings, encompassing rigorous quality control measures throughout the entire manufacturing process, ensuring that every medicine meets the highest standards of safety and efficacy. Ajanta Pharma operates with a global vision, serving diverse therapeutic areas such as cardiology, dermatology, ophthalmology, and pain management. This diversified approach enables the company to navigate the complexities of the pharmaceutical landscape and adapt to evolving healthcare needs. By consistently investing in research and innovation, Ajanta Pharma strives to be at the forefront of pharmaceutical advancements, developing solutions that address critical health challenges worldwide. The company's commitment to ethical business practices and patient-centric values underpins its mission to improve health outcomes and make a positive impact on communities worldwide.
Company Details
Key Leadership
Corporate Events
AJANTPHARM Share Price: Frequently Asked Questions
What is the current share price of Ajanta Pharma Ltd?
Ajanta Pharma Ltd (AJANTPHARM) trades at ₹3079.40 on NSE and BSE. Market cap ₹32.08K (Cr). Educational data only.
What is the P/E ratio of Ajanta Pharma Ltd?
Ajanta Pharma Ltd has a P/E of 32.94x vs industry average 31.77x.
What is the Bull Run score for Ajanta Pharma Ltd?
Ajanta Pharma Ltd has a Bull Run score of 53.5/100 based on 25+ financial parameters.
Does Ajanta Pharma Ltd pay dividends?
Ajanta Pharma Ltd has a dividend yield of 1.09%. Past dividends don't guarantee future payments.
What is the ROE of Ajanta Pharma Ltd?
Ajanta Pharma Ltd has ROE of 24.91%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ajanta Pharma Ltd?
Ajanta Pharma Ltd has debt-to-equity of 0.06.
Is Ajanta Pharma Ltd a good investment?
Bull Run gives Ajanta Pharma Ltd a score of 53.5/100. This is not investment advice — consult a SEBI-registered advisor.